Latest News and Press Releases

Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through...

Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and...

Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...

Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU,...

Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist...

Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...

As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...